Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD1222 + BNT162b2
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AZD1222 + BNT162b2 refers to a heterologous COVID-19 vaccination schedule combining the AstraZeneca vaccine (AZD1222) and the Pfizer-BioNTech vaccine (BNT162b2). This combination approach has been studied as a potential strategy to enhance immune responses, particularly when used as a booster following primary vaccination. AZD1222 is an adenovirus vector vaccine, while BNT162b2 is an mRNA vaccine. Studies have shown that mixing these vaccines can maintain high levels of immunogenicity and safety, with heterologous schedules potentially offering favorable immunogenicity compared to homologous schedules.
- Brand names
- ComirnatyVaxzevria
- Other names
- Oxford/AstraZeneca + Pfizer-BioNTechChAdOx1-S + BNT162b2Vaxzevria + Comirnaty
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on AZD1222 + BNT162b2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD1222 + BNT162b2.